---
schema_version: "secwatch.filing_event.v1"
accession: "0001326732-24-000046"
form_type: "8-K"
ticker: "XNCR"
cik: "0001326732"
company_name: "Xencor Inc"
filed_at: "2024-09-09T23:59:59+00:00"
generated_at: "2026-05-31T05:51:40.132893+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Xencor unveils autoimmune pipeline, reports initial XmAb819 RECIST responses in ccRCC

## Summary
- XmAb942 (anti-TL1A) Phase 1 healthy volunteer study starts Q4 2024; interim data in H1 2025.
- Plamotamab (CD20xCD3) Phase 1b/2a in multi-drug resistant RA to begin H1 2025.
- XmAb657 (CD19xCD3) Phase 1 in autoimmune disease starts H2 2025; preclinical B-cell depletion >99.98%.
- XmAb819 (ENPP3xCD3) shows RECIST responses in ccRCC; dose escalation continues, target dose by YE 2024.

## SEC filing metadata
- accession: 0001326732-24-000046
- form_type: 8-K
- ticker: XNCR
- cik: 0001326732
- company_name: Xencor Inc
- filed_at: 2024-09-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326732/000132673224000046/0001326732-24-000046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326732/000132673224000046/xncr-20240909.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326732-24-000046
- JSON: https://secwatch.observer/filing/0001326732-24-000046.json
- Plain text: https://secwatch.observer/filing/0001326732-24-000046.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.